{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T03:41:15Z","timestamp":1762659675724,"version":"3.40.5"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jad-journal.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.jad.2018.05.060","type":"journal-article","created":{"date-parts":[[2018,5,29]],"date-time":"2018-05-29T12:45:17Z","timestamp":1527597917000},"page":"122-128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Effect of agomelatine 25\u201350\u202fmg on functional outcomes in patients with major depressive disorder"],"prefix":"10.1016","volume":"238","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5339-7185","authenticated-orcid":false,"given":"Sidney H.","family":"Kennedy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinhard","family":"Heun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alla","family":"Avedisova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antti","family":"Ahokas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Olivier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7oise","family":"Picarel-Blanchot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"de Bodinat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jad.2018.05.060_bib0039","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1590\/1809-4503201400040003","article-title":"Factors associated with work ability in the elderly: systematic review","volume":"17","author":"Amorim","year":"2014","journal-title":"Rev Bras Epidemiol"},{"year":"2000","series-title":"Diagnostic and Statistical Manual of Mental Disorders, 4th Edn (DSM-IV-TR)","key":"10.1016\/j.jad.2018.05.060_bib0002"},{"key":"10.1016\/j.jad.2018.05.060_bib0003","doi-asserted-by":"crossref","first-page":"242","DOI":"10.4088\/JCP.12m08197","article-title":"Efficacy and safety of levomilnacipran sustained release 40mg, 80mg, or 120mg in major depressive disorder: a phase 3, randomized, double-blind, placebo-controlled study","volume":"74","author":"Asnis","year":"2013","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2018.05.060_bib0004","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2165\/00023210-200519040-00004","article-title":"Social functioning: should it become an endpoint in trials of antidepressants?","volume":"19","author":"Bech","year":"2005","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jad.2018.05.060_bib0005","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1600-0447.2008.01289.x","article-title":"A validation analysis of two self-reported HAM-D6 versions","volume":"119","author":"Bech","year":"2009","journal-title":"Acta Psychiatr. Scand."},{"issue":"Suppl 1","key":"10.1016\/j.jad.2018.05.060_bib0006","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/S0924-977X(97)00420-3","article-title":"Development and validation of a social functioning scale, the social adaptation self-evaluation scale","volume":"7","author":"Bosc","year":"1997","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2018.05.060_bib0007","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1192\/bjp.187.1.35","article-title":"Physical health and depressive symptoms in older Europeans. Results from EURODEP","volume":"187","author":"Braam","year":"2005","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2018.05.060_bib0008","doi-asserted-by":"crossref","first-page":"647","DOI":"10.2147\/NDT.S13171","article-title":"Improvement of social adaptation in depression with serotonin and norepinephrine reuptake inhibitors","volume":"6","author":"Briley","year":"2010","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.jad.2018.05.060_bib0009","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","article-title":"Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis","volume":"391","author":"Cipriani","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jad.2018.05.060_bib0010","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1017\/S1092852913000060","article-title":"A pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine versus escitalopram, fluoxetine, and sertraline","volume":"18","author":"Demyttenaere","year":"2013","journal-title":"CNS Spectr."},{"key":"10.1016\/j.jad.2018.05.060_bib0011","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1017\/S0033291706008981","article-title":"The concept of recovery in major depression","volume":"37","author":"Fava","year":"2007","journal-title":"Psychol. Med."},{"key":"10.1016\/j.jad.2018.05.060_bib0012","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\"Mini-mental state\". A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jad.2018.05.060_bib0013","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/mpr.358","article-title":"Testing the short and screener versions of the social adjustment scale-self-report (SAS-SR)","volume":"21","author":"Gameroff","year":"2012","journal-title":"Int. J. Methods Psychiatr. Res."},{"key":"10.1016\/j.jad.2018.05.060_bib0001","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/S0140-6736(17)32130-X","article-title":"Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the global burden of disease study 2016","volume":"390","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jad.2018.05.060_bib0014","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2165\/11530230-000000000-00000","article-title":"Defining and measuring functional recovery from depression","volume":"24","author":"Greer","year":"2010","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jad.2018.05.060_bib0015","doi-asserted-by":"crossref","DOI":"10.1111\/bph.12720","article-title":"Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties","author":"Guardiola-Lemaitre","year":"2014","journal-title":"Br. J. Pharmacol"},{"year":"1976","series-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","key":"10.1016\/j.jad.2018.05.060_bib0016"},{"key":"10.1016\/j.jad.2018.05.060_bib0017","article-title":"Functional recovery in major depressive disorder: focus on early optimized treatment","volume":"18","author":"Habert","year":"2016","journal-title":"Prim. Care Companion CNS Disord."},{"key":"10.1016\/j.jad.2018.05.060_bib0018","doi-asserted-by":"crossref","first-page":"587","DOI":"10.4088\/JCP.12m08250","article-title":"The efficacy of agomelatine in elderly patients with major recurrent depressive disorder: a placebo controlled study","volume":"74","author":"Heun","year":"2013","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2018.05.060_bib0019","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1176\/appi.ajp.157.9.1501","article-title":"Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness?","volume":"157","author":"Judd","year":"2000","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2018.05.060_bib0020","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1037\/0022-3514.91.2.316","article-title":"The evolutionary significance of depressive symptoms: different adverse situations lead to different depressive symptom patterns","volume":"91","author":"Keller","year":"2006","journal-title":"J. Pers. Soc. Psychol."},{"key":"10.1016\/j.jad.2018.05.060_bib0021","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.euroneuro.2015.09.006","article-title":"Sustained efficacy of agomelatine 10mg, 25mg, and 25-50mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled study over 6 months","volume":"26","author":"Kennedy","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2018.05.060_bib0022","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.euroneuro.2014.01.006","article-title":"A placebo-controlled study of three agomelatine dose regimens (10mg, 25mg, 25-50mg) in patients with major depressive disorder","volume":"24","author":"Kennedy","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2018.05.060_bib0023","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2165\/11534420-000000000-00000","article-title":"Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness","volume":"24","author":"Kennedy","year":"2010","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jad.2018.05.060_bib0024","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1001\/jama.289.23.3095","article-title":"The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)","volume":"289","author":"Kessler","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.jad.2018.05.060_bib0025","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/YIC.0000000000000031","article-title":"Predictors of functional improvement in employed adults with major depressive disorder treated with desvenlafaxine","volume":"29","author":"Lam","year":"2014","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2018.05.060_bib0026","article-title":"Beyond symptomatic improvement:assessing real-world outcomes in patients with major depressive disorder","volume":"12","author":"Langlieb","year":"2010","journal-title":"Prim. Care Companion J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2018.05.060_bib0027","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jad.2017.11.003","article-title":"Efficacy of antidepressants on measures of workplace functioning in major depressive disorder: a systematic review","volume":"227","author":"Lee","year":"2018","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2018.05.060_bib0028","first-page":"298","article-title":"Evaluation of the effect of duloxetine treatment on functioning as measured by the Sheehan disability scale: pooled analysis of data from six randomized, double-blind, placebo-controlled clinical studies","volume":"27","author":"Mancini","year":"2012","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2018.05.060_bib0040","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/JCP.0b013e31825d6c25","article-title":"Agomelaine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder. A pilot study","volume":"32","author":"Marttinotti","year":"2012","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"10.1016\/j.jad.2018.05.060_bib0029","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/hup.2424","volume":"29","author":"Montgomery","year":"2014","journal-title":"Hum. Psychopharmacol"},{"key":"10.1016\/j.jad.2018.05.060_bib0030","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1002\/gps.1789","article-title":"Depression and chronic medical illnesses in Asian older adults: the role of subjective health and functional status","volume":"22","author":"Niti","year":"2007","journal-title":"Int. J. Geriatr. Psychiatry"},{"issue":"Suppl 3","key":"10.1016\/j.jad.2018.05.060_bib0031","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00004850-199606003-00015","article-title":"The measurement of disability","volume":"11","author":"Sheehan","year":"1996","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2018.05.060_bib0032","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/YIC.0b013e3282f2b4d6","article-title":"Assessing treatment effects in clinical trials with the discan metric of the Sheehan Disability Scale","volume":"23","author":"Sheehan","year":"2008","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2018.05.060_bib0033","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.4088\/JCP.09m05133blu","article-title":"Assessing the efficacy of desvenlafaxine for improving functioning and well-being outcome measures in patients with major depressive disorder: a pooled analysis of 9 double-blind, placebo-controlled, 8-week clinical trials","volume":"70","author":"Soares","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2018.05.060_bib0034","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jad.2016.03.048","article-title":"Early effect on general interest, and short-term antidepressant efficacy and safety of agomelatine (25-50mg\/day) and escitalopram (10-20mg\/day) in outpatients with Major Depressive Disorder. A 12-week randomised double-blind comparative study","volume":"199","author":"Udristoiu","year":"2016","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2018.05.060_bib0035","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med. Care"},{"journal-title":"Depression","year":"2018","key":"10.1016\/j.jad.2018.05.060_bib0036"},{"key":"10.1016\/j.jad.2018.05.060_bib0037","first-page":"709","article-title":"Geriatric depression scale","volume":"24","author":"Yesavage","year":"1988","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.jad.2018.05.060_bib0038","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The hospital anxiety and depression scale","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatr. Scand."}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032718303434?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032718303434?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T20:30:50Z","timestamp":1535661050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032718303434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":40,"alternative-id":["S0165032718303434"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2018.05.060","relation":{},"ISSN":["0165-0327"],"issn-type":[{"type":"print","value":"0165-0327"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of agomelatine 25\u201350\u202fmg on functional outcomes in patients with major depressive disorder","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2018.05.060","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}